EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice



A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice



Journal of Infectious Diseases 210(6): 964-972



The incidence of Clostridium difficile infection (CDI) and associated mortality have increased rapidly worldwide in recent years. Therefore, it is critical to develop new therapies for CDI. In this study, we generated a novel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (VHH) binding domains against both TcdA and TcdB (designated "ABA") that reverses fulminant CDI in mice infected with an epidemic 027 strain after a single injection of the antibody. We demonstrated that ABA bound to both toxins simultaneously and displayed a significantly enhanced neutralizing activity both in vitro and in vivo. Additionally, ABA was able to broadly neutralize toxins from clinical C. difficile isolates that express both TcdA and TcdB but failed to neutralize the toxin from TcdA(-)TcdB(+) C. difficile strains. This study thus provides a rationale for the development of multivalent VHHs that target both toxins and are broadly neutralizing for treating severe CDI.

(PDF emailed within 0-6 h: $19.90)

Accession: 051197896

Download citation: RISBibTeXText

PMID: 24683195

DOI: 10.1093/infdis/jiu196



Related references

Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection. Pathogens and Disease 74(7): -, 2017

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. Journal of Infectious Diseases 207(2): 323-330, 2013

A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile. Bmc Infectious Diseases 16(1): 596-596, 2016

Sequence variation in tcdA and tcdB of Clostridium difficile: ST37 with truncated tcdA is a potential epidemic strain in China. Journal of Clinical Microbiology 52(9): 3264-3270, 2015

The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiology Letters 155(1): 45-54, 1997

Oral immunization with non-toxic C. difficile strains expressing chimeric fragments of TcdA and TcdB elicits protective immunity against C. difficile infection in both mice and hamsters. Infection and Immunity: -, 2018

Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. Journal of Clinical Microbiology 42(12): 5710-5714, 2004

Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area. Anaerobe 15(6): 266-269, 2010

CdtR Regulates TcdA and TcdB Production in Clostridium difficile. Plos Pathogens 12(7): E1005758-E1005758, 2017

Lectin activity of the TcdA and TcdB toxins of Clostridium difficile. Infection and Immunity 2018, 2018

Detection and transcriptional analysis of tcdA and tcdB in a non-toxigenic strain of Clostridium difficile. Abstracts of the General Meeting of the American Society for Microbiology 99: 45-46, 1999

Release of TcdA and TcdB from Clostridium difficile cdi 630 is not affected by functional inactivation of the tcdE gene. Microbial Pathogenesis 52(1): 92-100, 2012

Clostridium difficile Toxins TcdA and TcdB Cause Colonic Tissue Damage by Distinct Mechanisms. Infection and Immunity 84(10): 2871-2877, 2017

A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clinical and Vaccine Immunology 20(3): 377-390, 2013

Cellular uptake of Clostridium difficile TcdA and truncated TcdA lacking the receptor binding domain. Journal of Medical Microbiology 62(Pt 9): 1414-1422, 2013